300 related articles for article (PubMed ID: 17438106)
1. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.
Liu W; Baer MR; Bowman MJ; Pera P; Zheng X; Morgan J; Pandey RA; Oseroff AR
Clin Cancer Res; 2007 Apr; 13(8):2463-70. PubMed ID: 17438106
[TBL] [Abstract][Full Text] [Related]
2. Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy.
Morgan J; Jackson JD; Zheng X; Pandey SK; Pandey RK
Mol Pharm; 2010 Oct; 7(5):1789-804. PubMed ID: 20684544
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
[TBL] [Abstract][Full Text] [Related]
4. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
Chu TS; Chen JS; Lopez JP; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):979-84. PubMed ID: 18794444
[TBL] [Abstract][Full Text] [Related]
5. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy.
Robey RW; Steadman K; Polgar O; Bates SE
Cancer Biol Ther; 2005 Feb; 4(2):187-94. PubMed ID: 15684613
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
[TBL] [Abstract][Full Text] [Related]
7. Improvement of the efficacy of 5-aminolevulinic acid-mediated photodynamic treatment in human oral squamous cell carcinoma HSC-4.
Yamamoto M; Fujita H; Katase N; Inoue K; Nagatsuka H; Utsumi K; Sasaki J; Ohuchi H
Acta Med Okayama; 2013; 67(3):153-64. PubMed ID: 23804138
[TBL] [Abstract][Full Text] [Related]
8. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.
Burger H; van Tol H; Brok M; Wiemer EA; de Bruijn EA; Guetens G; de Boeck G; Sparreboom A; Verweij J; Nooter K
Cancer Biol Ther; 2005 Jul; 4(7):747-52. PubMed ID: 15970668
[TBL] [Abstract][Full Text] [Related]
9. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia.
Wang L; Giannoudis A; Lane S; Williamson P; Pirmohamed M; Clark RE
Clin Pharmacol Ther; 2008 Feb; 83(2):258-64. PubMed ID: 17568400
[TBL] [Abstract][Full Text] [Related]
10. ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.
Palasuberniam P; Yang X; Kraus D; Jones P; Myers KA; Chen B
Sci Rep; 2015 Aug; 5():13298. PubMed ID: 26282350
[TBL] [Abstract][Full Text] [Related]
11. Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based photocytotoxicity of gastric cancer cells in vitro.
Hagiya Y; Endo Y; Yonemura Y; Takahashi K; Ishizuka M; Abe F; Tanaka T; Okura I; Nakajima M; Ishikawa T; Ogura S
Photodiagnosis Photodyn Ther; 2012 Sep; 9(3):204-14. PubMed ID: 22959800
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.
McDowell HP; Meco D; Riccardi A; Tanno B; Berardi AC; Raschellà G; Riccardi R; Dominici C
Int J Cancer; 2007 Mar; 120(5):1141-9. PubMed ID: 17131346
[TBL] [Abstract][Full Text] [Related]
13. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
[TBL] [Abstract][Full Text] [Related]
14. Critical role of ABCG2 in ALA-photodynamic diagnosis and therapy of human brain tumor.
Ishikawa T; Kajimoto Y; Inoue Y; Ikegami Y; Kuroiwa T
Adv Cancer Res; 2015; 125():197-216. PubMed ID: 25640271
[TBL] [Abstract][Full Text] [Related]
15. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib.
Glodkowska-Mrowka E; Mrowka P; Basak GW; Niesiobedzka-Krezel J; Seferynska I; Wlodarski PK; Jakobisiak M; Stoklosa T
Exp Hematol; 2014 Jun; 42(6):439-47. PubMed ID: 24667683
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
17. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
[TBL] [Abstract][Full Text] [Related]
18. Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers.
Kim JH; Park JM; Roh YJ; Kim IW; Hasan T; Choi MG
BMC Cancer; 2015 Jul; 15():504. PubMed ID: 26149077
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
Turrini E; Haenisch S; Laechelt S; Diewock T; Bruhn O; Cascorbi I
Pharmacogenet Genomics; 2012 Mar; 22(3):198-205. PubMed ID: 22241070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
